江苏澳洋健康产业股份有限公司 独立董事述职报告 （徐国辉） 各位股东及股东代表： 本人作为江苏澳洋健康产业股份有限公司（以下简称"公司"）的独立董事， 在 2025 年度严格按照《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司独立董事管理 办法》等相关法律法规以及《公司章程》的规定和要求，本着对公司和广大股东 负责的态度，忠实勤勉地履行职责，充分发挥独立董事的作用，切实维护公司和 中小股东的权益。现将 2025 年度履职情况汇报如下： 一、基本情况 1、个人工作履历、专业背景以及兼职情况 男，中国国籍，汉族，生于 1971 年 8 月，硕士研究生学历，毕业于上海交 通大学。历任江苏澳洋健康产业股份有限公司独立董事，现任张家港保税区至信 新能源有限公司执行董事、总经理，上海烁阳新能源科技有限公司执行董事，张 家港至华新能源有限公司执行董事，张家港中拓新能源有限公司执行董事、总经 理，苏州广厦物业管理有限公司执行公司事务的董事，上海境灿新能源科技有限 公司执行董事，太仓中拓新能源有限公司执行董事、总经理，上海兆拓新能源科 技有限公司执行董事，苏州润 ...

（倪婷婷） 各位股东及股东代表： 本人作为江苏澳洋健康产业股份有限公司（以下简称"公司"）的独立董事， 在 2025 年度严格按照《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司独立董事管理 办法》等相关法律法规以及《公司章程》的规定和要求，本着对公司和广大股东 负责的态度，忠实勤勉地履行职责，充分发挥独立董事的作用，切实维护公司和 中小股东的权益。现将 2025 年度履职情况汇报如下： 一、基本情况 江苏澳洋健康产业股份有限公司 独立董事述职报告 1、个人工作履历、专业背景以及兼职情况 女，中国国籍，汉族，生于 1986 年 8 月，博士学历，教授，毕业于南京大 学会计学专业；现任南京财经大学会计学院教授、硕士生导师；现任南京大学环 境规划设计研究院集团股份公司独立董事、江苏澳洋健康产业股份有限公司独立 董事。 2、是否存在影响独立性的情况说明 2025 年，作为公司的独立董事，经自查，本人符合《上市公司独立董事管 理办法》等相关法律法规中对独立董事独立性的相关要求，不存在影响独立性的 情况。作为公司独立董事，本人不在公司兼任除董事会专门委员 ...

江苏澳洋健康产业股份有限公司 独立董事述职报告 （孙卓雅） 各位股东及股东代表： 本人作为江苏澳洋健康产业股份有限公司（以下简称"公司"）的独立董事， 在 2025 年度严格按照《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》《上市公司独立董事管理 办法》等相关法律法规以及《公司章程》的规定和要求，本着对公司和广大股东 负责的态度，忠实勤勉地履行职责，充分发挥独立董事的作用，切实维护公司和 中小股东的权益。现将 2025 年度履职情况汇报如下： 一、基本情况 1、个人工作履历、专业背景以及兼职情况 女，中国国籍，汉族，生于 1980 年 12 月，本科学历，毕业于南京大学法学 院。现就职于江苏漫修（上海）律师事务所、江苏澳洋健康产业股份有限公司独 立董事。 2、是否存在影响独立性的情况说明 2025 年，作为公司的独立董事，经自查，本人符合《上市公司独立董事管 理办法》等相关法律法规中对独立董事独立性的相关要求，不存在影响独立性的 情况。作为公司独立董事，本人不在公司兼任除董事会专门委员会委员外的其他 任何职务，与公司及其控股股东不存在可能妨碍本人进行独 ...

江苏澳洋健康产业股份有限公司 2025 年年度报告 江苏澳洋健康产业股份有限公司 2025 年年度报告全文 1 江苏澳洋健康产业股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 2026 年 03 月 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人沈学如、主管会计工作负责人王潇及会计机构负责人（会计 主管人员）王潇声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来计划、发展战略等前瞻性陈述，属于计划性事项， 不构成公司对投资者的实质性承诺，敬请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 截至报告期末，母公司存在未弥补亏损 23,292,423.39 元。 江苏澳洋健康产业股份有限公司 2025 年年度报告全文 备查文件目录 1、载有法定代表人签名的 2025 年年度报告原件； 2、载有法定代表人、主管会计工作负责人、会计机构负责人签名并盖章的财务报表； 3、报告期内在中国 ...

Group 1: Corporate Governance Changes - In September 2025, the controlling shareholder, Aoyang Group, transferred 20% of its shares to Zhangjiagang Yuesheng Technology Co., Ltd., changing the actual controller to the Zhangjiagang Economic and Technological Development Zone Management Committee, officially integrating the company into the local state-owned assets system [2] - In January 2026, the company completed a board restructuring, appointing Gao Yan as the new chairman, while the former chairman, Shen Xueru, became the vice chairman. The share transfer was completed in November 2025 [2] Group 2: Financial Performance - According to the Q3 2025 report, the company's net profit attributable to shareholders for the single quarter was 8.56 million yuan, a year-on-year increase of 533.86%, but the revenue for the first three quarters was 1.36 billion yuan, a year-on-year decrease of 9.39% [3] - The non-recurring net profit for Q3 increased by 63.23% year-on-year, indicating an improvement in the core business profitability [3] Group 3: Market Dynamics - On February 3, 2026, the net inflow of main funds was 448,000 yuan, with the stock price rising by 2.12% and a trading volume of 54.62 million yuan; however, on January 30, there was a net outflow of 6.93 million yuan, leading to a 2.07% drop in stock price [4] - Year-to-date, the stock price has increased by 9.32%, but it has decreased by 3.77% over the past 60 days, showing a volatile trend [4] Group 4: Industry Environment - The pharmaceutical and biotechnology industry benefits from long-term trends such as an aging population and supportive policies for innovative drugs, which may provide structural opportunities for the company's medical services business [5] - However, high valuations need to be matched by performance growth to avoid volatility risks [5]

Group 1 - The company, Aoyang Health (002172), emphasizes the importance of future development and is exploring various channels to strengthen and expand the listed company [1]

Group 1 - The core point of the article is that Aoyang Health (002172) has projected that by the end of 2025, the number of shareholders will reach 50,324 [1]

Core Insights - The medical services sector experienced a significant increase of 4.15% on January 13, with Norska leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Group 1: Stock Performance - Norska (301333) closed at 76.48, up 20.01% with a trading volume of 55,200 shares and a transaction value of 397 million yuan [1] - Yingsi (301257) also saw a rise of 20.00%, closing at 72.24 with a trading volume of 22,900 shares [1] - Hongbo Pharmaceutical (301230) increased by 20.00%, closing at 56.64 with a trading volume of 57,200 shares [1] - Lanwei Medical (301060) rose by 19.96%, closing at 13.28 with a trading volume of 135,210 shares [1] - Boji Pharmaceutical (300404) increased by 19.96%, closing at 12.92 with a trading volume of 627,100 shares [1] - Dian Diagnostics (300244) saw an increase of 11.90%, closing at 29.16 with a trading volume of 1,516,000 shares [1] Group 2: Capital Flow - The medical services sector saw a net inflow of 1.497 billion yuan from institutional investors, while retail investors experienced a net outflow of 713 million yuan [2] - The main stocks with significant capital flow include International Medical (000516) with a net inflow of 259 million yuan from institutional investors [3] - Boji Pharmaceutical (300404) had a net inflow of 243 million yuan from institutional investors, but also saw a net outflow of 140 million yuan from retail investors [3]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]

Core Viewpoint - The report highlights the growth trends in China's synthetic fiber industry, indicating a production increase and providing insights into market dynamics from 2026 to 2032 [1] Industry Overview - In November 2025, China's synthetic fiber production reached 6.88 million tons, reflecting a year-on-year growth of 5.7% [1] - From January to November 2025, the cumulative production of synthetic fibers in China was 72.404 million tons, with a cumulative growth rate of 4.9% [1] Companies Mentioned - The report lists several key companies in the synthetic fiber sector, including Hengyi Petrochemical, Rongsheng Petrochemical, Xin Fengming, Tongkun Co., Hengli Petrochemical, Jilin Chemical Fiber, Huafeng Chemical, Aoyang Health, Taihe New Materials, and Jiangnan High Fiber [1] Research and Consulting - The insights are derived from a report by Zhiyan Consulting, a leading industry consulting firm in China, which specializes in providing in-depth industry research reports, business plans, feasibility studies, and customized services [1]